Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
dipeptidyl aminopeptidase-IV inhibitors	4114	361442-04-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: saxagliptin onglyza saxagliptin hydrochloride saxagliptin hydrate saxagliptin HCl BMS-477118 BMS 477118	inhibits Dipeptidyl Peptidase-4 Molecular weight: 315.42 Formula: C18H25N3O2 CLOGP: 0.25 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 90.35 ALOGS: -2.14 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

saxagliptin
onglyza
saxagliptin hydrochloride
saxagliptin hydrate
saxagliptin HCl
BMS-477118
BMS 477118

inhibits Dipeptidyl Peptidase-4

Molecular weight: 315.42
Formula: C18H25N3O2
CLOGP: 0.25
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 90.35
ALOGS: -2.14
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
5	mg	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.23 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
S (Water solubility)	63 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	24 %	Hosey CM, Chan R, Benet LZ
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	1.80 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	7.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	7.50 hours	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	0.87 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	-0.002		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	3.873		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	3.357	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	1.581	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	80.940	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	80.650	%	High	1
herg	hERG pIC50	4.230	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	1.119	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	3.155	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	87.190	%	High	1
kinase-safety-class	CDK5,EIF2AK3,GRK2,PDK1,PDK2,PDK4	6
kinase-selectivity-class	PDK1	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	2.328		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	5.702		High	1
mppb	Mouse plasma protein binding (% unbound)	87.750		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	7.345		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	91.060	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	2.692	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	91.660	%	High	1
rppb	Rat plasma protein binding (% unbound)	85.310	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	928.966	uM	High	1

Approvals:

Date	Agency	Company	Orphan
July 31, 2009	FDA	ASTRAZENECA AB
Sept. 30, 2009	EMA	ASTRAZENECA AB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Lactic acidosis	63.31	20.15	34	3690	50429	90574294
Hypoglobulinaemia	62.17	20.15	10	3714	169	90624554
Diabetic ketoacidosis	50.12	20.15	23	3701	24384	90600339
Ketoacidosis	47.93	20.15	15	3709	5580	90619143
Acute kidney injury	44.47	20.15	60	3664	320327	90304396
Urinary tract obstruction	41.68	20.15	11	3713	2238	90622485
Blood glucose increased	33.08	20.15	29	3695	95217	90529506
Subacute cutaneous lupus erythematosus	32.35	20.15	10	3714	3572	90621151
Drug interaction	29.86	20.15	46	3678	276407	90348316
Febrile bone marrow aplasia	29.23	20.15	12	3712	9726	90614997
Inappropriate antidiuretic hormone secretion	26.87	20.15	14	3710	19491	90605232
Arrhythmia	25.84	20.15	18	3706	42314	90582409
Pancreatitis	25.73	20.15	22	3702	69804	90554919
Hypoglycaemia	23.71	20.15	21	3703	69827	90554896
Cardiac failure	22.43	20.15	25	3699	109471	90515252
Dehydration	21.88	20.15	33	3691	194414	90430309
Hypogammaglobulinaemia	21.72	20.15	10	3714	10664	90614059
Hypoglycaemic coma	21.43	20.15	7	3717	2983	90621740
Small intestinal obstruction	20.34	20.15	12	3712	21222	90603501
Cerebral infarction	20.30	20.15	13	3711	26583	90598140

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pancreatic carcinoma	71.91	19.74	29	4122	9477	42607707
Vertigo	50.64	19.74	35	4116	34312	42582872
Infection parasitic	45.12	19.74	10	4141	407	42616777
Insulin C-peptide decreased	44.80	19.74	7	4144	37	42617147
Diabetic ketoacidotic hyperglycaemic coma	40.66	19.74	8	4143	180	42617004
Gastrointestinal bacterial infection	40.09	19.74	10	4141	681	42616503
Pancreatitis	39.23	19.74	33	4118	43235	42573949
Dizziness	38.86	19.74	79	4072	249175	42368009
Blood glucose increased	34.31	19.74	39	4112	73660	42543524
Hypoglycaemia	31.88	19.74	34	4117	59820	42557364
Diabetes mellitus inadequate control	30.79	19.74	19	4132	15371	42601813
Dyspepsia	30.39	19.74	28	4123	41324	42575860
Hypoglycaemic coma	30.17	19.74	11	4140	2733	42614451
Angina pectoris	29.62	19.74	25	4126	32871	42584313
Acute kidney injury	28.23	19.74	89	4062	367248	42249936
Pancreatitis acute	27.17	19.74	24	4127	33540	42583644
Faeces soft	27.16	19.74	12	4139	4900	42612284
Abdominal pain upper	26.08	19.74	36	4115	82573	42534611
Volvulus	25.65	19.74	9	4142	2004	42615180
Large intestine polyp	25.31	19.74	14	4137	9251	42607933
Spleen congestion	24.94	19.74	6	4145	351	42616833
Post procedural erythema	24.71	19.74	3	4148	0	42617184
B-cell lymphoma	23.98	19.74	11	4140	4902	42612282
Drug effect less than expected	23.20	19.74	10	4141	3847	42613337
Suprapubic pain	23.11	19.74	6	4145	480	42616704
Ketoacidosis	23.08	19.74	11	4140	5341	42611843
Anal fissure	20.28	19.74	10	4141	5229	42611955

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pancreatic carcinoma	73.41	17.31	30	7325	14842	110567102
Ketoacidosis	69.80	17.31	26	7329	10061	110571883
Hypoglobulinaemia	68.06	17.31	12	7343	217	110581727
Acute kidney injury	67.01	17.31	137	7218	635293	109946651
Lactic acidosis	60.90	17.31	50	7305	92761	110489183
Hypoglycaemia	56.95	17.31	53	7302	116051	110465893
Hypoglycaemic coma	52.41	17.31	18	7337	5515	110576429
Pancreatitis	52.36	17.31	46	7309	93487	110488457
Diabetic ketoacidosis	51.30	17.31	33	7322	42025	110539919
Blood glucose increased	49.25	17.31	52	7303	132444	110449500
Insulin C-peptide decreased	41.72	17.31	7	7348	93	110581851
Infection parasitic	41.32	17.31	10	7345	884	110581060
Diabetic ketoacidotic hyperglycaemic coma	40.55	17.31	8	7347	271	110581673
Diabetes mellitus inadequate control	37.89	17.31	24	7331	29751	110552193
Gastrointestinal bacterial infection	36.74	17.31	10	7345	1408	110580536
Cerebral infarction	36.25	17.31	29	7326	51809	110530135
Vertigo	35.70	17.31	36	7319	86834	110495110
Dehydration	35.10	17.31	65	7290	279446	110302498
Cardiac failure	34.80	17.31	52	7303	187574	110394370
Pancreatitis acute	34.44	17.31	30	7325	60244	110521700
Large intestine polyp	32.10	17.31	17	7338	15100	110566844
Pemphigoid	30.49	17.31	18	7337	19689	110562255
Hypogammaglobulinaemia	30.18	17.31	18	7337	20058	110561886
Angina pectoris	29.68	17.31	28	7327	62267	110519677
B-cell lymphoma	27.22	17.31	12	7343	7142	110574802
Spleen congestion	25.22	17.31	6	7349	493	110581451
Subacute cutaneous lupus erythematosus	24.39	17.31	10	7345	4984	110576960
Volvulus	24.09	17.31	9	7346	3509	110578435
Renal cancer	23.08	17.31	13	7342	13021	110568923
Faeces soft	22.10	17.31	12	7343	11198	110570746
Post procedural erythema	21.70	17.31	3	7352	9	110581935
Peripheral arterial occlusive disease	21.31	17.31	11	7344	9269	110572675
Hyperglycaemia	20.88	17.31	27	7328	85063	110496881
Urinary tract obstruction	20.72	17.31	9	7346	5168	110576776
Drug effect less than expected	20.72	17.31	10	7345	7310	110574634
Glycosylated haemoglobin increased	20.43	17.31	15	7340	23604	110558340
Suprapubic pain	20.38	17.31	6	7349	1119	110580825
Arrhythmia	20.16	17.31	24	7331	69551	110512393
Inappropriate antidiuretic hormone secretion	19.64	17.31	17	7338	33834	110548110
Urosepsis	19.01	17.31	16	7339	30659	110551285
Anal fissure	17.89	17.31	10	7345	9871	110572073
Scab	17.67	17.31	11	7344	13225	110568719

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10BD10	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BD21	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BD25	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BH03	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Dipeptidyl peptidase 4 (DPP-4) inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006728	Hormones
MeSH PA	D007004	Hypoglycemic Agents
MeSH PA	D011480	Protease Inhibitors
MeSH PA	D054795	Incretins
MeSH PA	D054873	Dipeptidyl-Peptidase IV Inhibitors
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:68612	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor
CHEBI has role	CHEBI:35554	cardiovascular drug

Related Drugs by ATC class:

A10BD Combinations of oral blood glucose lowering drugs 19 drugs

acarbose alogliptin canagliflozin dapagliflozin empagliflozin ertugliflozin evogliptin gemigliptin glimepiride linagliptin lobeglitazone metformin show all 19 →

A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 9 drugs

alogliptin evogliptin gemigliptin linagliptin rosuvastatin simvastatin sitagliptin teneligliptin vildagliptin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Alcoholism	contraindication	7200002
Asthenia	contraindication	13791008
Myocardial infarction	contraindication	22298006	DOID:5844
Acute vomiting	contraindication	23971007
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Dehydration	contraindication	34095006
Infectious disease	contraindication	40733004
End stage renal disease	contraindication	46177005	DOID:784
Lymphocytopenia	contraindication	48813009	DOID:614
Ketoacidosis	contraindication	56051008
Acute nephropathy	contraindication	58574008
Metabolic acidosis	contraindication	59455009
Hypopituitarism	contraindication	74728003	DOID:9406
Cardiogenic shock	contraindication	89138009
Kidney disease	contraindication	90708001	DOID:557
Lactic acidosis	contraindication	91273001	DOID:3650
Cobalamin deficiency	contraindication	190634004
Decompensated cardiac failure	contraindication	195111005
Disease of liver	contraindication	235856003	DOID:409
Hypoglycemic disorder	contraindication	237630007
Sepsis syndrome	contraindication	238150007
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Fever	contraindication	386661006
Surgical procedure	contraindication	387713003
Severe diarrhea	contraindication	409587002
Traumatic injury	contraindication	417746004
Radiography with IV Iodinated Contrast Agent	contraindication
Severe Hypoxemia	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.77	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	QTERN	ASTRAZENECA AB	N209091	Feb. 27, 2017	DISCN	TABLET	ORAL	6515117	Oct. 4, 2025	TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	QTERN	ASTRAZENECA AB	N209091	May 2, 2019	DISCN	TABLET	ORAL	6515117	Oct. 4, 2025	TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM;EQ 5MG BASE	QTERNMET XR	ASTRAZENECA AB	N210874	May 2, 2019	DISCN	TABLET, EXTENDED RELEASE	ORAL	6515117	Oct. 4, 2025	TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE	QTERNMET XR	ASTRAZENECA AB	N210874	May 2, 2019	DISCN	TABLET, EXTENDED RELEASE	ORAL	6515117	Oct. 4, 2025	TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE	QTERNMET XR	ASTRAZENECA AB	N210874	May 2, 2019	DISCN	TABLET, EXTENDED RELEASE	ORAL	6515117	Oct. 4, 2025	TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE	QTERNMET XR	ASTRAZENECA AB	N210874	May 2, 2019	DISCN	TABLET, EXTENDED RELEASE	ORAL	6515117	Oct. 4, 2025	TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	QTERN	ASTRAZENECA AB	N209091	Feb. 27, 2017	DISCN	TABLET	ORAL	8501698	June 20, 2027	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN
10MG;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	QTERN	ASTRAZENECA AB	N209091	Feb. 27, 2017	DISCN	TABLET	ORAL	8501698	June 20, 2027	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN
10MG;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	QTERN	ASTRAZENECA AB	N209091	Feb. 27, 2017	DISCN	TABLET	ORAL	8501698	June 20, 2027	TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	QTERN	ASTRAZENECA AB	N209091	May 2, 2019	DISCN	TABLET	ORAL	8501698	June 20, 2027	TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM;EQ 5MG BASE	QTERNMET XR	ASTRAZENECA AB	N210874	May 2, 2019	DISCN	TABLET, EXTENDED RELEASE	ORAL	8501698	June 20, 2027	TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE	QTERNMET XR	ASTRAZENECA AB	N210874	May 2, 2019	DISCN	TABLET, EXTENDED RELEASE	ORAL	8501698	June 20, 2027	TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE	QTERNMET XR	ASTRAZENECA AB	N210874	May 2, 2019	DISCN	TABLET, EXTENDED RELEASE	ORAL	8501698	June 20, 2027	TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE	QTERNMET XR	ASTRAZENECA AB	N210874	May 2, 2019	DISCN	TABLET, EXTENDED RELEASE	ORAL	8501698	June 20, 2027	TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	QTERN	ASTRAZENECA AB	N209091	Feb. 27, 2017	DISCN	TABLET	ORAL	8361972	March 21, 2028	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN
10MG;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	QTERN	ASTRAZENECA AB	N209091	Feb. 27, 2017	DISCN	TABLET	ORAL	8361972	March 21, 2028	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN
10MG;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	QTERN	ASTRAZENECA AB	N209091	Feb. 27, 2017	DISCN	TABLET	ORAL	8361972	March 21, 2028	TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	QTERN	ASTRAZENECA AB	N209091	May 2, 2019	DISCN	TABLET	ORAL	8361972	March 21, 2028	TREATMENT OF TYPE 2 DIABETES MELLITUS

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1GM;EQ 2.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	KOMBIGLYZE XR	ASTRAZENECA AB	N200678	Nov. 5, 2010	DISCN	TABLET, EXTENDED RELEASE	ORAL	Oct. 11, 2027	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
1GM;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	KOMBIGLYZE XR	ASTRAZENECA AB	N200678	Nov. 5, 2010	DISCN	TABLET, EXTENDED RELEASE	ORAL	Oct. 11, 2027	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
500MG;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	KOMBIGLYZE XR	ASTRAZENECA AB	N200678	Nov. 5, 2010	DISCN	TABLET, EXTENDED RELEASE	ORAL	Oct. 11, 2027	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Dipeptidyl peptidase 4	Enzyme	P27487	DPP4_HUMAN	INHIBITOR	Ki	9.22	CHEMBL	CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN				WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN				WOMBAT-PK
Dipeptidyl peptidase 8	Enzyme	Q6V1X1	DPP8_HUMAN		Ki	6.89	CHEMBL
Dipeptidyl peptidase 9	Enzyme	Q86TI2	DPP9_HUMAN		Ki	7.15	CHEMBL
Dipeptidyl peptidase 4	Enzyme		DPP4_MOUSE		IC50	8.72	CHEMBL

External reference:

ID	Source
4029055	VUID
N0000179814	NUI
D08996	KEGG_DRUG
709031-78-7	SECONDARY_CAS_RN
4029055	VANDF
4029067	VANDF
C1611934	UMLSCUI
CHEBI:71272	CHEBI
CHEMBL2103745	ChEMBL_ID
CHEMBL1201743	ChEMBL_ID
DB06335	DRUGBANK_ID
C502994	MESH_SUPPLEMENTAL_RECORD_UI
11243969	PUBCHEM_CID
6316	IUPHAR_LIGAND_ID
9GB927LAJW	UNII
1043560	RXNORM
166611	MMSL
26648	MMSL
32427	MMSL
369212	MMSL
d07467	MMSL
013204	NDDF
013205	NDDF
443066009	SNOMEDCT_US
443087004	SNOMEDCT_US
734452007	SNOMEDCT_US
BJM	PDB_CHEM_ID
CHEMBL385517	ChEMBL_ID
945667-22-1	SECONDARY_CAS_RN
9GB927LAJW	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Saxagliptin and Metformin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	43598-618	TABLET, FILM COATED, EXTENDED RELEASE	2.50 mg	ORAL	ANDA	27 sections
Saxagliptin and Metformin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	43598-619	TABLET, FILM COATED, EXTENDED RELEASE	5 mg	ORAL	ANDA	27 sections
Saxagliptin and Metformin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	43598-620	TABLET, FILM COATED, EXTENDED RELEASE	5 mg	ORAL	ANDA	27 sections
ONGLYZA	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6309	TABLET, FILM COATED	5 mg	ORAL	NDA	31 sections
Saxagliptin	Human Prescription Drug Label	1	65862-825	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	27 sections
Saxagliptin	Human Prescription Drug Label	1	65862-826	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
SAXAGLIPTIN	HUMAN PRESCRIPTION DRUG LABEL	1	68462-726	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	28 sections
SAXAGLIPTIN	HUMAN PRESCRIPTION DRUG LABEL	1	68462-727	TABLET, FILM COATED	5 mg	ORAL	ANDA	28 sections

Ask DrugCentral

Try a sample question

saxagliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: